Literature DB >> 22972412

Comparison of the behavioral and cardiovascular effects of mephedrone with other drugs of abuse in rats.

Kurt J Varner1, Kyle Daigle, Peter F Weed, Peter B Lewis, Sarah E Mahne, Ananthakrishnan Sankaranarayanan, Peter J Winsauer.   

Abstract

RATIONALE: Exceedingly little experimental research exists on the popular recreational drug mephedrone (4-methylmethcathinone) despite clinical reports concerning its behavioral and cardiovascular toxicity.
OBJECTIVES: To characterize mephedrone preclinically by examining its capacity to (1) serve as a discriminative stimulus, (2) disrupt the acquisition of response sequences, and (3) disrupt mean arterial pressure (MAP) and heart rate (HR). METHODS AND
RESULTS: In one group of subjects that reliably discriminated 3.2 mg/kg of mephedrone from saline (n = 9), substitution tests indicated that stimulants (cocaine, MDMA, and methamphetamine) more closely approximated the mephedrone discriminative stimulus than non-stimulants (fenfluramine, morphine, and phencyclidine), although none fully substituted. In a second group (n = 6), mephedrone (0.56-10 mg/kg, i.p.) dose-dependently decreased response rate and increased errors in both components of a procedure in which subjects either acquired a new response sequence each session (repeated acquisition) or completed the same response sequence each session (performance). Finally, in a third group (n = 12), radio telemetry probes were used to measure the changes in MAP and HR elicited by mephedrone and then compared them to a known stimulant, methamphetamine. In these studies, mephedrone (0.01-9 mg/kg, i.v.) elicited increases in MAP and HR that were very similar to those elicited by methamphetamine (0.01-9 mg/kg, i.v.). The tachycardia and pressor responses to mephedrone (3 mg/kg) were blocked by the β-blocker atenolol (1 mg/kg, i.v.) and the α1, α2-blocker phentolamine (3 mg/kg, i.v.), respectively.
CONCLUSIONS: Mephedrone produces behavioral and cardiovascular responses that are similar to other stimulants; however, differences from the classical stimulants were also apparent.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22972412      PMCID: PMC3538107          DOI: 10.1007/s00213-012-2855-1

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  35 in total

1.  "Legal highs" on the net-Evaluation of UK-based Websites, products and product information.

Authors:  Martin M Schmidt; Akhilesh Sharma; Fabrizio Schifano; Charlotte Feinmann
Journal:  Forensic Sci Int       Date:  2010-07-21       Impact factor: 2.395

Review 2.  Chemistry, pharmacology, and metabolism of emerging drugs of abuse.

Authors:  Hans H Maurer
Journal:  Ther Drug Monit       Date:  2010-10       Impact factor: 3.681

3.  Headshop heartache: acute mephedrone 'meow' myocarditis.

Authors:  Patrick J Nicholson; Martin J Quinn; Jonathan D Dodd
Journal:  Heart       Date:  2010-11-09       Impact factor: 5.994

4.  Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity.

Authors:  David M Wood; Susannah Davies; Malgorzata Puchnarewicz; Jenny Button; Roland Archer; Hanna Ovaska; John Ramsey; Terry Lee; David W Holt; Paul I Dargan
Journal:  J Med Toxicol       Date:  2010-09

Review 5.  The cardiovascular and cardiac actions of ecstasy and its metabolites.

Authors:  S K Shenouda; F Carvalho; K J Varner
Journal:  Curr Pharm Biotechnol       Date:  2010-08       Impact factor: 2.837

6.  Long-term behavioral and pharmacodynamic effects of delta-9-tetrahydrocannabinol in female rats depend on ovarian hormone status.

Authors:  Peter J Winsauer; Jill M Daniel; Catalin M Filipeanu; Stuart T Leonard; Jerielle L Hulst; Shaefali P Rodgers; Caroline L Lassen-Greene; Jessie L Sutton
Journal:  Addict Biol       Date:  2011-01       Impact factor: 4.280

7.  Mephedrone: use, subjective effects and health risks.

Authors:  Adam Winstock; Luke Mitcheson; John Ramsey; Susannah Davies; Malgorzata Puchnarewicz; John Marsden
Journal:  Addiction       Date:  2011-07-27       Impact factor: 6.526

8.  Oxidative stress contributes to methamphetamine-induced left ventricular dysfunction.

Authors:  Kevin C Lord; Sylvia K Shenouda; Elizabeth McIlwain; Dimitrios Charalampidis; Pamela A Lucchesi; Kurt J Varner
Journal:  Cardiovasc Res       Date:  2010-02-05       Impact factor: 10.787

9.  Discriminative stimulus effects of psychostimulants and hallucinogens in S(+)-3,4-methylenedioxymethamphetamine (MDMA) and R(-)-MDMA trained mice.

Authors:  K S Murnane; N Murai; L L Howell; W E Fantegrossi
Journal:  J Pharmacol Exp Ther       Date:  2009-08-14       Impact factor: 4.030

Review 10.  Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues.

Authors:  Fabrizio Schifano; Antonio Albanese; Suzanne Fergus; Jackie L Stair; Paolo Deluca; Ornella Corazza; Zoe Davey; John Corkery; Holger Siemann; Norbert Scherbaum; Magi' Farre'; Marta Torrens; Zsolt Demetrovics; A Hamid Ghodse
Journal:  Psychopharmacology (Berl)       Date:  2010-11-12       Impact factor: 4.530

View more
  30 in total

1.  Methiopropamine and its acute behavioral effects in mice: is there a gray zone in new psychoactive substances users?

Authors:  Fabio De-Giorgio; Sabrine Bilel; Micaela Tirri; Raffaella Arfè; Claudio Trapella; Cristian Camuto; Federica Foti; Paolo Frisoni; Margherita Neri; Francesco Botrè; Matteo Marti
Journal:  Int J Legal Med       Date:  2020-05-01       Impact factor: 2.686

2.  Mephedrone interactions with cocaine: prior exposure to the 'bath salt' constituent enhances cocaine-induced locomotor activation in rats.

Authors:  Ryan A Gregg; Christopher S Tallarida; Allen B Reitz; Scott M Rawls
Journal:  Behav Pharmacol       Date:  2013-12       Impact factor: 2.293

Review 3.  The preclinical pharmacology of mephedrone; not just MDMA by another name.

Authors:  A R Green; M V King; S E Shortall; K C F Fone
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

4.  Discriminative-stimulus effects of second generation synthetic cathinones in methamphetamine-trained rats.

Authors:  Jennifer E Naylor; Kevin B Freeman; Bruce E Blough; William L Woolverton; Sally L Huskinson
Journal:  Drug Alcohol Depend       Date:  2015-02-11       Impact factor: 4.492

5.  The Supplement Adulterant β-Methylphenethylamine Increases Blood Pressure by Acting at Peripheral Norepinephrine Transporters.

Authors:  Charles W Schindler; Eric B Thorndike; Kenner C Rice; John S Partilla; Michael H Baumann
Journal:  J Pharmacol Exp Ther       Date:  2019-03-21       Impact factor: 4.030

6.  Discriminative and locomotor effects of five synthetic cathinones in rats and mice.

Authors:  Michael B Gatch; Margaret A Rutledge; Michael J Forster
Journal:  Psychopharmacology (Berl)       Date:  2014-10-05       Impact factor: 4.530

7.  3,4-Methylenedioxypyrovalerone prevents while methylone enhances methamphetamine-induced damage to dopamine nerve endings: β-ketoamphetamine modulation of neurotoxicity by the dopamine transporter.

Authors:  John H Anneken; Mariana Angoa-Pérez; Donald M Kuhn
Journal:  J Neurochem       Date:  2015-03-02       Impact factor: 5.372

8.  Locomotor activity and discriminative stimulus effects of a novel series of synthetic cathinone analogs in mice and rats.

Authors:  Michael B Gatch; Sean B Dolan; Michael J Forster
Journal:  Psychopharmacology (Berl)       Date:  2017-02-16       Impact factor: 4.530

9.  Evaluation of training dose in male Sprague-Dawley rats trained to discriminate 4-methylmethcathinone.

Authors:  Michael D Berquist; Nathyn A Thompson; Lisa E Baker
Journal:  Psychopharmacology (Berl)       Date:  2017-08-16       Impact factor: 4.530

10.  In vivo effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity.

Authors:  William E Fantegrossi; Brenda M Gannon; Sarah M Zimmerman; Kenner C Rice
Journal:  Neuropsychopharmacology       Date:  2012-11-08       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.